Therapeutic article of manufacture with nanoparticles to promote wound healing and/or antimicrobial infection control
A therapeutic article of manufacture that includes a body having fibers treated with a mixture including metal-modified cerium oxide nanoparticles (mCNPs) and one or more of a polymeric binder, a dispersant and a stabilizer. The mCNPs have a predominant 3+ surface charge and in a range of about 3-35 nanometers (nm) in size. The mCNPs are mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of the mixture having the mCNPs and the one or more of a polymeric binder, a dispersant and a stabilizer. The metal (m) is an antimicrobial promoting metal that is non-ionizing. A method is also provided that promotes wound healing and/or antimicrobial infection control with a barrier of the therapeutic article of manufacture.
1 . A therapeutic article of manufacture comprising:
a body having fibers treated with a mixture including metal-modified cerium oxide nanoparticles (mCNPs) having a predominant 3+ surface charge and in a range of about 3-35 nanometers (nm) in size and one or more of a polymeric binder, a dispersant, a stabilizer or combinations thereof, the mCNPs are mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of the mixture and m is an antimicrobial promoting metal that is non-ionizing wherein the body further includes an anti-inflammatory dressing or an analgesic dressing, and wherein the mCNPs consist of AgCNP2 and the metal is a stable metallic silver that is non-ionizing and a Janus-type two-phase construct.
2 . The therapeutic article of manufacture according to claim 1 , wherein the fibers include one or more of polymers, yarns, cotton, synthetic polymer fibers or combinations thereof.
3 . The therapeutic article of manufacture according to claim 1 , wherein the body further comprises:
a first layer including the treated fibers;
a second layer including a waterproof layer having a first side and a second side; and
a high-grab and/or instant tack adhesive on the second side.
4 . The therapeutic article of manufacture according to claim 3 , further comprising a third layer of at least one peel-off liner overlaying the treated fibers and the high-grab and/or instant tack adhesive.
5 . The therapeutic article of manufacture according to claim 1 , wherein the therapeutic article comprises additional mCNPs and the metal (m) of the additional mCNPs is selected from the group consisting of silver, gold, ruthenium, vanadium, copper, titanium, nickel, platinum, tin, zinc or iron.
6 . The therapeutic article of manufacture according to claim 1 , wherein the mixture includes the polymeric binder, the dispersant and the stabilizer and the dispersant and the stabilizer promote adhesion with the polymeric binder and the fibers.
7 . The therapeutic article of manufacture according to claim 1 , wherein the body further includes biological or naturally derived agents.
8 . The therapeutic article of manufacture according to claim 1 , wherein the body further includes a surgical wound dressing form factor.
9 . The therapeutic article of manufacture according to claim 1 , wherein:
the mixture further includes a therapeutic dosage of epithelial tissue healing agent; and
the treated fibers are impregnated fibers impregnated with or formed of the mixture.
10 . The therapeutic article of manufacture according to claim 9 , wherein the body further comprises a non-adherent semipermeable membrane or non-adherent porous material on top of and surrounding the treated fibers, so that the therapeutic dosage of epithelial tissue healing agent is dispensed through the non-adherent semipermeable membrane or the non-adherent porous material.
11 . The therapeutic article of manufacture according to claim 1 , wherein the treated fibers eradicate Rhinovirus 14, SARS-COV-2 surrogate OC43 coronavirus and Parainfluenza virus type 5 trapped by the fibers.
12 . The therapeutic article of manufacture according to claim 1 , wherein the treated fibers eradicate Streptococcus mutans and Staphylococcus aureus trapped by the treated fibers.
13 . A method comprising:
applying a barrier using a therapeutic article of manufacture of claim 1 , over a portion of an anatomical body part to protect the portion of the anatomical body part;
trapping, by the barrier, at least one of a bacteria or virus to treat the at least one bacteria or virus by the barrier; and
eradicating, by the barrier, the at least one of the bacteria and virus.
14 . The method according to claim 13 , wherein the virus includes at least one of Rhinovirus 14, SARS-COV-2 surrogate OC43 coronavirus or Parainfluenza virus type 5.
15 . The method according to claim 13 , wherein the portion of the anatomical body part includes a wound, incision or laceration.
16 . The method according to claim 13 , wherein the applying of the barrier includes adhesively affixing the therapeutic article of manufacture with a high-grab and/or instant tack adhesive to skin of the portion of the anatomical body part.
17 . The method according to claim 13 , wherein the bacteria includes at least one of Streptococcus mutans or Staphylococcus aureus.
18 . The method according to claim 13 , wherein the mixture of the therapeutic article of manufacture includes a therapeutic dosage of epithelial tissue healing agent; and treated fibers of the therapeutic article of manufacture are impregnated fibers impregnated with or formed of the mixture.
19 . The method according to claim 13 , wherein the mixture of the therapeutic article of manufacture includes a polymeric binder, a dispersant and a stabilizer and the dispersant and the stabilizer promote adhesion with the polymeric binder and fibers of a body of the therapeutic article of manufacture.